US EditionNovo Nordisk’s Shock 2026 Guidance Points to Obesity Battle Heating Up
- Novo Nordisk on Tuesday said sales and adjusted operating profit could decline up to 13% this year, citing heavy U.S. price pressure and competition.
- Policy and market shifts — including MFN pricing — have lowered realised prices and patent losses for semaglutide, while Eli Lilly's tirzepatide and copycat drugs cut U.S. Wegovy market share.
- Accounting adjustments reveal a 14% drop in operating profit to 31.7 billion crowns, impacted by a $4.2 billion rebate reversal, as of February 3, 2026.
- Investors will tune into the Feb 4 conference call at 13.00 CEST, as Novo's U.S.-listed shares fell 12% after the earlier-than-expected earnings statement, according to CEO Mike Doustdar.
- As GLP-1 volumes expand, the company expects adjusted sales growth and adjusted operating profit growth at CER to decline between-5% and-13%, betting on the Wegovy pill and CagriSema to regain U.S. share.
34 Articles
34 Articles
Treatment Advances Position Lilly as Weight-Loss Heavyweight
For every patient Eli Lilly helped downsize with its obesity drug Zepbound, rival Novo Nordisk’s purse got a little lighter, too. After Novo reported disappointing results Tuesday, all eyes are on Eli’s earnings today, evaluating whether the firm has what it takes to, once and for all, take the Danish firm’s krone. Foes Woes Sales of Lilly’s GLP-1 treatments for diabetes and weight loss accelerated in 2025, winning investor confidence and sendin…
The US actions of the Danish producer Novo Nordisk were delayed by 14% on Tuesday after a temporary suspension of the transaction, following the announcement that sales and profit will decrease this year due to the lowest prices in the US and the loss of its exclusiveity for its medicines seen in China, Brazil and Canada, according to the CNBC.
Stock Market Today, Feb. 3: Novo Nordisk Slides as Pricing Pressure Clouds Obesity-Drug Outlook
Novo Nordisk (NYSE:NVO), a diabetes and obesity drug maker, closed Tuesday at $50.33, down 14.59%. The stock sold off after management projected a 2026 sales and profit decline despite strong recent results, and investors are watching how it defends U.S. obesity-drug share and pricing. The company’s trading volume reached 67.7 million shares, which is about 218% above its three-month average of 21.3 million shares. Novo Nordisk went public in 19…
Novo and Lilly are locked in an increasingly fierce battle in the heated obesity drug market, with strong price pressure in the US under the Trump administration.
Wegovy Woes: Novo Nordisk Faces Profit Slump Amid Fierce Competition
Wegovy Woes: Novo Nordisk Faces Profit Slump Amid Fierce Competition Novo Nordisk, the maker of the obesity drug Wegovy, announced a potential drop in profits and sales by up to 13% this year. This marks the first time in years the company has faced such declines, primarily due to competitive pressures and pricing interventions by former U.S. President Donald Trump.The Danish company's growth, which had seen double-digit increases since Wegovy's…
Coverage Details
Bias Distribution
- 44% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
